Quarterly report pursuant to Section 13 or 15(d)

Segments

v3.19.3
Segments
9 Months Ended
Sep. 30, 2019
Segment Reporting [Abstract]  
SEGMENTS SEGMENTS
We manage our operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and our pharmaceutical research and development. The diagnostics segment primarily consists of our clinical laboratory operations through BioReference and our point-of-care operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.
Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:
 
For the three months ended September 30,
 
For the nine months ended September 30,
(In thousands)
2019
 
2018
 
2019
 
2018
Revenue from services:
 
 
 
 
 
 
 
Pharmaceutical
$

 
$

 
$

 
$

Diagnostics
181,139

 
202,811

 
538,488

 
630,180

Corporate

 

 

 

 
$
181,139

 
$
202,811

 
$
538,488

 
$
630,180

Revenue from products:
 
 
 
 
 
 
 
Pharmaceutical
$
26,161

 
$
25,395

 
$
80,143

 
$
81,769

Diagnostics

 

 

 

Corporate

 

 

 

 
$
26,161

 
$
25,395

 
$
80,143

 
$
81,769

Revenue from transfer of intellectual property and other:
 
 
 
 
 
 
 
Pharmaceutical
$
21,472

 
$
21,609

 
$
58,961

 
$
56,463

Diagnostics

 

 

 

Corporate

 

 

 

 
$
21,472

 
$
21,609

 
$
58,961

 
$
56,463

Operating loss:
 
 
 
 
 
 
 
Pharmaceutical
$
(14,232
)
 
$
(16,937
)
 
$
(52,265
)
 
$
(37,721
)
Diagnostics
(16,363
)
 
(11,082
)
 
(77,945
)
 
(17,624
)
Corporate
(8,416
)
 
(5,445
)
 
(31,378
)
 
(25,839
)
 
$
(39,011
)
 
$
(33,464
)
 
$
(161,588
)
 
$
(81,184
)
Depreciation and amortization:
 
 
 
 
 
 
 
Pharmaceutical
$
7,673

 
$
7,021

 
$
22,580

 
$
20,514

Diagnostics
16,116

 
16,880

 
48,647

 
52,855

Corporate
16

 
20

 
54

 
71

 
$
23,805

 
$
23,921

 
$
71,281

 
$
73,440

Loss from investment in investees:
 
 
 
 
 
 
 
Pharmaceutical
$
(294
)
 
$
(1,603
)
 
$
(2,419
)
 
$
(10,715
)
Diagnostics

 
(271
)
 

 
(827
)
Corporate

 

 

 

 
$
(294
)
 
$
(1,874
)
 
$
(2,419
)
 
$
(11,542
)
Revenues:
 
 
 
 
 
 
 
United States
$
189,485

 
$
208,646

 
$
558,688

 
$
646,492

Ireland
22,968

 
24,407

 
65,675

 
62,468

Chile
8,436

 
8,926

 
25,352

 
32,596

Spain
4,172

 
4,144

 
13,466

 
14,269

Israel
1,938

 
2,283

 
8,822

 
8,424

Mexico
1,642

 
1,382

 
5,231

 
4,105

Other
131

 
27

 
358


58

 
$
228,772

 
$
249,815

 
$
677,592

 
$
768,412


(In thousands)
September 30,
2019
 
December 31,
2018
Assets:
 
 
 
Pharmaceutical
$
1,235,513

 
$
1,236,499

Diagnostics
1,114,485

 
1,162,160

Corporate
19,520

 
52,413

 
$
2,369,518

 
$
2,451,072

Goodwill:

 

Pharmaceutical
$
243,011

 
$
247,407

Diagnostics
452,787

 
452,786

Corporate

 

 
$
695,798

 
$
700,193



No customer represented more than 10% of our total consolidated revenue during the three and nine months ended September 30, 2019 and 2018. As of September 30, 2019 and December 31, 2018, no customer represented more than 10% of our accounts receivable balance.